C. Aceves, P. Garcia-Solis, O. Arroyo-Helguera, L. Vega-Riveroll, G. Delgado and B. Anguiano, “Antineoplastic Effect of Iodine in Mammary Cancer: Participation of 6-Iodolactone (6-IL) and Peroxisome Proliferator-Activated Receptors (PPAR),” Molecular Cancer, Vol. 8, No. 1, 2009, p. 33. doi:10.1186/1476-4598-8-33

has been cited by the following article:

• TITLE: Urine Iodine, Estrogen, and Breast Disease

  AUTHORS: Alexander E. Poor, Bernard A. Eskin, Christine Georgiadis, Brian Hamzavi, Ari D. Brooks

  KEYWORDS: Breast Cancer; Iodine; Iodide; Estrogen

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.6, December 27, 2012

  ABSTRACT: Introduction: We sought to explore iodine status (expressed as urine iodine excretion) in a group of women with a variety of breast diseases to characterize the relationship between iodine and breast physiology. Methods: Demographic and clinical data were recorded and random urine iodine levels were checked in 415 euthyroid patients over 5 years during clinic visits. Results: Pre menopausal women excreted less iodine in their urine than post menopausal women. Post menopausal women who took hormone supplementation had an excretion level similar to pre menopausal women. Women with breast cancer excreted less iodine than those without, and iodine excretion increased after treatment with aromatase inhibitors. Conclusions: These results demonstrate that there is a relationship between estrogen status and iodine excretion in euthyroid women. This suggests that there may be a threshold for total body iodine required for prevention of breast disease.